Fujifilm continues its biotech building spree with new facility in China
A Japanese conglomerate is making a big play in China with the opening of a new facility, as it continues to expand.
Fujifilm Irvine Scientific has opened its new Innovation and Collaboration Center in Suzhou New District, China, an area in Jiangsu province specifically designated for technological and industrial development.
According to Fujifilm, the 12,000-square-foot site will be responsible for the company’s cell culture media optimization, analysis and design services. Cell culture media itself often requires customization of formulas and protocols to achieve the desired quantity and quality of therapeutic desired. Fujifilm Irvine Scientific is offering these services from its headquarters in California and Japan to its customers globally, as well as in China now.
Fujifilm Irvine Scientific did not disclose the sum of the facility’s cost to Endpoints News.
“In the past decade, the world has seen rapid growth in China’s biopharmaceutical, vaccine, cell and gene therapy markets. The speed of approval of biosimilar drugs and investment by the government to make more affordable drugs available to its people is accelerating that growth,” said Bob Newman, chief science officer of Fujifilm Irvine Scientific in an email.
Newman also acknowledged that the market for cell culture media in China has been expanding rapidly and is expected to continue to grow as researchers and drug manufacturers need bioprocesses to drive down the cost of therapeutics.
Fujifilm is also increasing the number of sales and technical support staff throughout China to meet the needs and support the antibody industry in China. However, the company did not disclose the number of workers being hired.
This opening comes as Fujifilm is making other major moves and investments globally.
Last year, the company announced that it was expanding its Armstrong R&D Center of Excellence in California to commit to the advancement of discovery research, bioproduction and cell and gene therapies. That same year, the company also opened a new drug manufacturing site in Tilburg, Netherlands. In March of this year, Fujifilm acquired recombinant protein maker Shenandoah Biotechnology for an undisclosed amount, allowing it to easily transition between preclinical and clinical phases of trials.